Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza

This article was originally published in The Pink Sheet Daily

Executive Summary

With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is still planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.


Related Content

Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?
MannKind Shares Game Plan For Tackling Afrezza's Complete Response
Spin On MannKind's Four-Week Delay For Afrezza Goes Both Ways
New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts